CTOs on the Move

HilleVax

www.hillevax.com

 
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.hillevax.com
  • 75 State Street Suite 100
    Boston, MA USA 02109
  • Phone: 617.213.5054

Executives

Name Title Contact Details
Anju Chatterji
Chief Technical Officer Profile

Similar Companies

Gilva Biotechnology

Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centrillion Biosciences

Centrillion Biosciences is a leading genomic and bioinformatics solution provider.

Intrexon Corporation

Intrexon Corporation is a privately held synthetic biology company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.

Hyasynth Bio

Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.

CiVi Biopharma

CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company`s research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi`s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.